DK1636586T3 - Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser - Google Patents

Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser

Info

Publication number
DK1636586T3
DK1636586T3 DK04756257T DK04756257T DK1636586T3 DK 1636586 T3 DK1636586 T3 DK 1636586T3 DK 04756257 T DK04756257 T DK 04756257T DK 04756257 T DK04756257 T DK 04756257T DK 1636586 T3 DK1636586 T3 DK 1636586T3
Authority
DK
Denmark
Prior art keywords
enzyme
nucleic acid
enhanced
acid sequences
metal deposition
Prior art date
Application number
DK04756257T
Other languages
English (en)
Inventor
Christopher Bieniarz
Casey A Kernag
Jerome W Kosmeder
Paula M Rodgers
Jennifer Wong
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of DK1636586T3 publication Critical patent/DK1636586T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/093Polyol derivatives esterified at least twice by phosphoric acid groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Chemically Coating (AREA)
  • Manufacture Of Alloys Or Alloy Compounds (AREA)
DK04756257T 2003-06-24 2004-06-24 Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser DK1636586T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48259603P 2003-06-24 2003-06-24
PCT/US2004/020700 WO2005003777A2 (en) 2003-06-24 2004-06-24 Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences

Publications (1)

Publication Number Publication Date
DK1636586T3 true DK1636586T3 (da) 2009-11-23

Family

ID=33563868

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04756257T DK1636586T3 (da) 2003-06-24 2004-06-24 Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser

Country Status (10)

Country Link
US (1) US7632652B2 (da)
EP (1) EP1636586B1 (da)
JP (1) JP4648902B2 (da)
AT (1) ATE437369T1 (da)
AU (1) AU2004254386B2 (da)
CA (2) CA2530287C (da)
DE (1) DE602004022165D1 (da)
DK (1) DK1636586T3 (da)
ES (1) ES2330441T3 (da)
WO (1) WO2005003777A2 (da)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2442282A1 (en) * 2001-03-29 2002-10-10 Cellect Technologies Corp. Methods devices and systems for sorting and separating particles
US7888060B2 (en) * 2001-03-30 2011-02-15 Nanoprobes, Inc. Method for detecting a target using enzyme directed deposition of elemental metal
US7691598B2 (en) * 2001-03-30 2010-04-06 Nanoprobes, Inc. Method for detecting a target molecule by metal deposition
US7642064B2 (en) * 2003-06-24 2010-01-05 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
US20060246523A1 (en) 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
DK2963011T3 (da) 2005-11-23 2018-08-06 Ventana Med Syst Inc Molekylært konjugat
WO2008063378A2 (en) 2006-11-01 2008-05-29 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
JP4920553B2 (ja) * 2006-11-08 2012-04-18 富士フイルム株式会社 イムノクロマトグラフキット
JP2010528285A (ja) 2007-05-23 2010-08-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド 免疫組織化学およびinsituハイブリダーゼーションのためのポリマー担体
FR2924601A1 (fr) * 2007-12-07 2009-06-12 Oreal Composes diphosphate d'hydroquinone et leur utilisation pour depigmenter la peau.
WO2009149013A2 (en) 2008-06-05 2009-12-10 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
WO2010022332A1 (en) 2008-08-22 2010-02-25 Ventana Medical Systems, Inc. Method for chromogenic detection of two or more target molecules in a single sample
KR101027036B1 (ko) * 2009-05-28 2011-04-11 주식회사 인포피아 금 이온의 환원에 의한 측방유동 분석에서의 신호 증폭 방법 및 이를 이용한 측방유동 분석 디바이스
EP2519647A1 (en) 2009-12-31 2012-11-07 Ventana Medical Systems, Inc. Methods for producing uniquely specific nucleic acid probes
US20120301886A1 (en) 2010-02-26 2012-11-29 Michael Farrell Polytag probes
DK2564203T3 (da) 2010-04-27 2017-08-21 Ventana Med Syst Inc Antistof-nanopartikelkonjugater og fremgangsmåder til fremstilling og anvendelse af sådanne konjugater
EP2588144B1 (en) 2010-07-02 2018-05-09 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
WO2012055060A1 (en) 2010-10-28 2012-05-03 Eth Zurich Method for electrical detection of biomolecules by metal dissolution and assay kit therefore
ES2689593T3 (es) 2010-12-30 2018-11-14 Ventana Medical Systems, Inc. Depósito potenciado de cromógenos que utilizan análogos de piridina
US8703439B1 (en) 2011-01-31 2014-04-22 Linda Lester Point of care iodine sensor
US9562259B2 (en) 2011-03-14 2017-02-07 Ventana Medical Systems, Inc. Method of analyzing chromosomal inversions
CN103649335B (zh) 2011-05-04 2015-11-25 Htg分子诊断有限公司 定量核酸酶保护测定(qnpa)和测序(qnps)的改进
WO2013167387A1 (en) 2012-05-10 2013-11-14 Ventana Medical Systems, Inc. Uniquely specific probes for pten, pik3ca, met, top2a, and mdm2
WO2014009535A2 (en) 2012-07-12 2014-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
WO2014048942A1 (en) 2012-09-25 2014-04-03 Ventana Medical Systems, Inc. Probes for pten, pik3ca, met, and top2a, and method for using the probes
US9938523B2 (en) * 2013-03-15 2018-04-10 Arizona Board Of Regents On Behalf Of Arizona State University Nucleic acid-tagged compositions and methods for multiplexed protein-protein interaction profiling
WO2015036405A1 (en) 2013-09-10 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating basal cell carcinoma
WO2015069787A1 (en) 2013-11-05 2015-05-14 Htg Molecular Diagnostics, Inc. Methods for detecting nucleic acids
CA2940118C (en) 2014-02-24 2023-05-23 Ventana Medical Systems, Inc. Automated rna detection using labeled 2'-o-methyl rna oligonucleotide probes and signal amplification systems
AU2015270575B2 (en) 2014-06-06 2019-07-25 Ventana Medical Systems, Inc. Significance of intratumoral HER2 heterogeneity in breast cancer and uses therefore
EP3201628B1 (en) 2014-10-02 2020-11-18 Ventana Medical Systems, Inc. Polymers and conjugates comprising the same
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
ES2791950T3 (es) 2015-02-03 2020-11-06 Ventana Med Syst Inc Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1)
WO2016146654A1 (en) 2015-03-16 2016-09-22 Ventana Medical Systems, Inc. Materials and methods for detecting androgen receptor splice variants and uses thereof
WO2016166169A1 (en) 2015-04-17 2016-10-20 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
WO2016189065A1 (en) 2015-05-26 2016-12-01 Ventana Medical Systems, Inc. Method and system for assessing stain quality for in-situ hybridization and immunohistochemistry
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
WO2017132276A1 (en) 2016-01-26 2017-08-03 Ventana Medical Systems, Inc. Predictive diagnostic workflow for tumors usnig automated dissection, next generation sequencing, and automated slide stainers
AU2017229370B2 (en) 2016-03-08 2021-03-11 Ventana Medical Systems, Inc. Multiplexed immunohistochemistry using recombinant antibodies with epitope tags
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
EP3463452A1 (en) 2016-05-24 2019-04-10 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
WO2018011107A1 (en) 2016-07-11 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of er-alpha 46 in methods and kits for assessing the status of breast cancer
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2018046736A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
EP3515453A1 (en) 2016-09-22 2019-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
WO2018055014A1 (en) 2016-09-23 2018-03-29 Ventana Medical Systems, Inc. Methods and systems for scoring extracellular matrix biomarkers in tumor samples
EP3541958A1 (en) 2016-11-15 2019-09-25 Ventana Medical Systems, Inc. Compositions and methods for prognosing and treating colorectal cancer
EP3554556B1 (en) 2016-12-19 2022-03-09 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
EP4220164B1 (en) 2016-12-19 2024-08-21 Ventana Medical Systems, Inc. Methods and systems for quantitative immunohistochemistry
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
WO2018146239A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker for outcome in aml patients
WO2018162404A1 (en) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker for outcome in aml patients
WO2018172540A1 (en) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to predict the progression of alzheimer's disease
WO2018189215A1 (en) 2017-04-12 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from hepatocellular carcinoma
US12566174B2 (en) 2017-05-11 2026-03-03 The Research Foundation For The State University Of New York Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid
CN107189988B (zh) * 2017-07-17 2019-08-30 江南大学 一株分泌抗丁香酚单克隆抗体的杂交瘤细胞株cs12及其应用
EP3659110A1 (en) 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
WO2019038219A1 (en) 2017-08-21 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
WO2019043138A1 (en) 2017-09-01 2019-03-07 INSERM (Institut National de la Santé et de la Recherche Médicale) METHOD FOR PREDICTING OUTCOME OF CANCER
EP3692368A1 (en) 2017-09-25 2020-08-12 Institut National de la Sante et de la Recherche Medicale (INSERM) Use of vnn1 as a biomarker and a therapeutic target in sarcomas
CN111491667A (zh) 2017-12-18 2020-08-04 文塔纳医疗系统公司 肽核酸缀合物
DK3746790T3 (da) 2018-01-31 2023-12-11 Ventana Med Syst Inc Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
EP3797296B1 (en) 2018-05-21 2024-09-04 Genentech, Inc. Her2 heterogeneity as a biomarker in cancer
WO2020016266A1 (en) 2018-07-17 2020-01-23 Ventana Medical Systems, Inc. Materials and methods for detecting fusion proteins
EP3850367B1 (en) 2018-09-13 2024-11-06 Ventana Medical Systems, Inc. Histochemical and cytochemical methods for detecting ntrk fusion proteins
CN112789684B (zh) 2018-10-01 2025-05-09 文塔纳医疗系统公司 用于预测对pd-1轴导向疗法的应答的方法和系统
WO2020089428A1 (en) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
WO2020089432A1 (en) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
JP7548903B2 (ja) 2018-11-20 2024-09-10 ヴェンタナ メディカル システムズ, インク. 形態学的特徴およびバイオマーカー発現のために細胞サンプルを調製および分析するための方法およびシステム
EP3906415B1 (en) 2019-01-03 2026-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
JP2022522265A (ja) 2019-01-16 2022-04-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エリスロフェロンの変異体及びその使用
EP3921648A1 (en) 2019-02-05 2021-12-15 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iv colorectal cancer
WO2020165370A1 (en) 2019-02-13 2020-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020182932A1 (en) 2019-03-13 2020-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) New gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
WO2020216832A1 (en) 2019-04-24 2020-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the response of antipsychotic drugs
WO2020229521A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for inhibiting or reducing bacterial biofilms on a surface
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
WO2021044012A1 (en) 2019-09-05 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment and pronostic of acute myeloid leukemia
US20240301497A1 (en) 2019-10-17 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
EP4110823A1 (en) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
US20230113705A1 (en) 2020-02-28 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
US20230086718A1 (en) 2020-03-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from a cancer
WO2021224293A1 (en) 2020-05-07 2021-11-11 Ventana Medical Systems, Inc. Histochemical systems and methods for evaluating egfr and egfr ligand expression in tumor samples
JP2023528978A (ja) 2020-06-10 2023-07-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 悪性膠芽腫のような癌の治療及び予防方法
US20230218608A1 (en) 2020-06-18 2023-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2022018163A1 (en) 2020-07-22 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting survival time in patients suffering from cancer
WO2022063787A1 (en) 2020-09-22 2022-03-31 Roche Diagnostics Gmbh Antibodies specific for alpha-1,6-core-fucosylated psa and fucosylated fragments thereof
WO2022064049A1 (en) 2020-09-28 2022-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing brucella infection
EP4232603A1 (en) 2020-10-20 2023-08-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Method for predicting the response to tnf inhibitors
EP4240874A1 (en) 2020-11-06 2023-09-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for diagnosis and treating polycystic ovary syndrome (pcos)
WO2022136252A1 (en) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for prognosis the humoral response of a subject prior to vaccination
WO2022135753A1 (en) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for prognosis the humoral response of a subject prior to vaccination
WO2022152698A1 (en) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of npdk-d to evaluate cancer prognosis
WO2022171611A1 (en) 2021-02-09 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to pronostic lung cancer
US20240159760A1 (en) 2021-03-17 2024-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing pancreatic cancer
WO2022207566A1 (en) 2021-03-29 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to evaluate pancreatic cancer prognosis
US20240158861A1 (en) 2021-04-23 2024-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cell senescence accumulation related disease
EP4367269A1 (en) 2021-07-05 2024-05-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
US20250067745A1 (en) 2022-01-31 2025-02-27 Institut National de la Santé et de la Recherche Médicale Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023152133A1 (en) 2022-02-08 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing colorectal cancer
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)
WO2024115935A1 (en) 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
WO2024236131A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Stratificate and method to treat a patient suffering from a cancer
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
WO2025027127A1 (en) 2023-08-02 2025-02-06 Institut National de la Santé et de la Recherche Médicale New prognostic method of kidney failure
WO2025045894A1 (en) 2023-08-28 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods and kits for diagnosing cause of nephrotic syndrome and guiding therapy
WO2025068340A1 (en) 2023-09-27 2025-04-03 Institut National de la Santé et de la Recherche Médicale Method to predict aml outcome
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
WO2025109147A1 (en) 2023-11-24 2025-05-30 Institut National de la Santé et de la Recherche Médicale Method to predict the risk of a cardiovascular event in a patient with type 2 diabetes
WO2025114473A1 (en) 2023-11-29 2025-06-05 Institut National de la Santé et de la Recherche Médicale Method for assessing diseases associated with a loss of p53 function in subjects in need thereof
WO2026013153A1 (en) 2024-07-10 2026-01-15 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from myc-high tumors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491098A (en) * 1987-03-09 1996-02-13 Janssen Pharmaceutica N.V. Method for depositing metal particles on a marker
FR2680374B2 (fr) * 1988-03-25 1993-11-12 Bioprobe Systems Sa Procede de coloration d'acides nucleiques detectes par marquage non radioactif et ensemble de reactifs pour la mise en óoeuvre de ce procede.
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5116734A (en) * 1989-09-01 1992-05-26 Digene Diagnostics, Inc. Highly sensitive method for detecting peroxidase
US5252743A (en) 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US5595707A (en) * 1990-03-02 1997-01-21 Ventana Medical Systems, Inc. Automated biological reaction apparatus
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
US5355439A (en) * 1991-08-05 1994-10-11 Bio Tek Instruments Method and apparatus for automated tissue assay
US5696887A (en) * 1991-08-05 1997-12-09 Biotek Solutions, Incorporated Automated tissue assay using standardized chemicals and packages
DE69233501T2 (de) * 1991-11-22 2006-02-23 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Kombinatorische Strategien für die Polymersynthese
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5412087A (en) * 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5631734A (en) * 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
WO1995030774A1 (en) * 1994-05-05 1995-11-16 Beckman Instruments, Inc. Oligonucleotide repeat arrays
US5571639A (en) * 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5599695A (en) * 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US6093574A (en) * 1997-08-11 2000-07-25 Ventana Medical Systems Method and apparatus for rinsing a microscope slide
US6083726A (en) * 1998-02-03 2000-07-04 Lucent Technologies, Inc. Methods for polynucleotide synthesis and articles for polynucleotide hybridization
US6451683B1 (en) * 2000-08-28 2002-09-17 Micron Technology, Inc. Damascene structure and method of making
US6670113B2 (en) * 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
GB0125532D0 (en) * 2001-10-24 2001-12-12 Burton Michael Enzyme activity indicators

Also Published As

Publication number Publication date
DE602004022165D1 (de) 2009-09-03
CA2773566C (en) 2015-09-15
ATE437369T1 (de) 2009-08-15
EP1636586B1 (en) 2009-07-22
JP4648902B2 (ja) 2011-03-09
WO2005003777A3 (en) 2005-06-09
AU2004254386B2 (en) 2009-09-24
CA2773566A1 (en) 2005-01-13
WO2005003777A2 (en) 2005-01-13
JP2007528986A (ja) 2007-10-18
CA2530287C (en) 2012-06-19
US20040265922A1 (en) 2004-12-30
CA2530287A1 (en) 2005-01-13
US7632652B2 (en) 2009-12-15
ES2330441T3 (es) 2009-12-10
AU2004254386A1 (en) 2005-01-13
EP1636586A2 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
DK1636586T3 (da) Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser
DE69736293D1 (de) Verfahren und zusammensetzung zur auffindung von cervix-krebs
DK1092155T3 (da) Fremgangsmåde til tidlig diagnose af carcinomer
EP1379693A4 (en) BIO STICK CODES BASED ON OLIGONUCLEOTIDE-MODIFIED PARTICLES
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
ATE556323T1 (de) Neurofibrilläre marker
ATE541054T1 (de) Bio-barcode erkennung für zielmoleküle
DE60228557D1 (de) Candida-nachweis
Elsner et al. Burial condition is the most important factor for mtDNA PCR amplification success in Palaeolithic equid remains from the Alpine foreland
WO2012050963A2 (en) Agents providing controls and standards for immuno-precipitation assays
WO2006034278A3 (en) Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
WO2005123954A3 (en) Methods for target molecule detection using siderophores and related compositions
IL176479A0 (en) Methods and compositions for identifying rna-binding proteins
Namdarghanbari et al. Toxic metal proteomics: Reaction of the mammalian zinc proteome with Cd2+
BRPI0414283A (pt) métodos, composições e kits para a concentração e detecção de microorganismos
DK1104547T3 (da) In vitro-fremgangsmåde til påvisning og diagnosticering af akutte koronarsyndromer
DK1945764T3 (da) Fremgangsmåde til isolering af mRNA fra formalinfekseret væv, der er indlejret i parafin
DE60012723D1 (de) Verfahren zur bestimmung von disaccharidasen
WO2007095378A3 (en) Mass tagging for quantitative analysis of biomolecules using 13c labeled phenylisocyanate
WO2002078636A3 (en) Detection and treatment of colorectal cancer
WO2002075314A3 (en) Detection and treatment of prostate cancer
DE602005024254D1 (da)
WO2008036474A3 (en) A method to detect tumor markers and diagnosis of undifferenciated tumors
DE60225059D1 (de) Verfahren um molekül-molekül interaktionen in proteomanalyse festzustellen
DK1171157T3 (da) Anvendelse af glucose-6-phosphat-isomerase og antistoffer derimod til diagnosticering og behandling af arthritis, og test for anti-arthritis-forbindelser